psoriasis

News

New biotech Avere plots listing via NextCure merger

New biotech Avere has taken a fast-track to becoming a listed company by merging with NextCure and raising $305m for an oral IL-23 drug for psoriasis.

News

Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest

New data with Takeda's TYK2 inhibitor zasocitinib suggest it is significantly more effective than BMS's Sotyktu in the treatment of psoriasis.

News

J&J gets FDA okay for psoriasis drug icotrokinra

Johnson & Johnson's much-anticipated oral IL-23 drug, icotrokinra, has claimed FDA approval as Icotyde for first-line treatment of plaque psoriasis.

News

Dr Jörn Drappa, Alumis' chief medical officer

Alumis shoots up as its Sotyktu rival aces psoriasis trials

Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after two positive phase 3 trials.

News

Takeda plans filings for Sotyktu rival on new psoriasis data

Takeda intends to file for approval of its oral psoriasis therapy zasocitinib next year, with Bristol Myers Squibb's Sotyktu in its sights.

News

Innovent gets OK for China's first home-grown IL-23p19 drug

Innovent has picked up approval in China for Pecondle, its anti-IL-23p19 antibody, as a treatment for moderate-to-severe plaque psoriasis.

New biotech Avere plots listing via NextCure merger

Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest

J&J gets FDA okay for psoriasis drug icotrokinra

Alumis shoots up as its Sotyktu rival aces psoriasis trials

Takeda plans filings for Sotyktu rival on new psoriasis data

Innovent gets OK for China's first home-grown IL-23p19 drug

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

psoriasis

Editor's Picks